Abstract:Unique lindenane sesquiterpenoid dimers from Chloranthecae spp. were recently identified with promising in vitro antiplasmodial activity and potentially novel mechanisms of action. To gain mechanistic insights to this new class of natural products, in vitro selection of Plasmodium falciparum resistance to the most active antiplasmodial compound, chlorajaponilide C, was explored. In all selected resistant clones, the half-maximal effective concentration (EC50) of chlorajaponilide C increased >250-fold, and whole genome sequencing revealed mutations in the recently discovered P. falciparum prodrug activation and resistance esterase (PfPARE). Chlorajaponilide C was highly potent (mean EC50 = 1.6 nM, n = 34) against fresh Ugandan P. falciparum isolates. The analysis of the structure-resistance relationships revealed that in vitro potency of a subset of lindenane sesquiterpenoid dimers was not mediated by PfPARE mutations. Thus, chlorajaponilide C, but not some related compounds, required parasite esterase activity for in vitro potency, and those compounds serve as the foundation for development of potent and selective antimalarials.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsinfecdis.0c00487?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00487</a>.Dose response curves for chlorajaponilide C in 3D7-WT and Dd2 strains and EC50 values of chlorajaponilide C in 3D7-R1 after 3 months without drug pressure (Figure S1); amino acid sequence alignment for Pf3D7_0709700 (PlasmoDB), 3D7-WT, and 3D7-R1–4 strains (Figure S2); Western blot showing expression of WT-PARE in the 3D7-R1 strain (Figure S3); dose response curves for fortunilide G in 3D7-WT and P. falciparum resistant strains (Figure S4); purity of lindenane sesquiterpenoid dimers (Table S1) (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00487/suppl_file/id0c00487_si_001.pdf">PDF</a>)All genomic variants identified in each of the individual strains compared to the 3D7 reference strain in PlasmoDB as well as the identified genomic variants in the resistant clones with respect to 3D7-WT (Table S2) (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00487/suppl_file/id0c00487_si_002.xlsx">XLSX</a>)This article has not yet been cited by other publications.

A kalihinol analog disrupts apicoplast function and vesicular trafficking in P. falciparum malaria

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

Identification of Potent and Reversible Piperidine Carboxamides That Are Species-Selective Orally Active Proteasome Inhibitors to Treat Malaria

Discovery of 1,3,4-oxadiazoles with slow-action activity against Plasmodium falciparum malaria parasites

Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

Discovery of dual-target natural antimalarial agents against DHODH and PMT of Plasmodium falciparum: pharmacophore modelling, molecular docking, quantum mechanics, and molecular dynamics simulations

Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

A novel multiple-stage antimalarial agent that inhibits protein synthesis

N-Substituted Phenylhydrazones Kill the Ring Stage of Plasmodium falciparum

Antimalarial drug discovery against malaria parasites through haplopine modification: An advanced computational approach

Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization

Poly-basic peptides and polymers as new drug candidate against Plasmodium falciparum

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo

Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity

Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase

2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Plasmodium falciparum Phosphatidylinositol-4-kinase and Hemozoin Formation with In Vivo Efficacy

Exploring Heme and Hemoglobin Binding Regions of Plasmodium Heme Detoxification Protein for New Antimalarial Discovery

Hybrid Peptide-Alkoxyamine Drugs: A Strategy for the Development of a New Family of Antiplasmodial Drugs

Identification of potential inhibitors of casein kinase 2 alpha of Plasmodium falciparum with potent in vitro activity